Provides for coverage of screenings for elevated lead levels exempting them from annual deductibles or coinsurance.
Impact
The bill's enactment would significantly impact state laws concerning health insurance coverage, particularly in relation to preventive health measures for children. The amendment ensures that families can access necessary screenings without incurring out-of-pocket costs, thus potentially increasing participation rates in lead testing. This could lead to earlier identification of lead exposure in children, which is critical in mitigating the long-term effects associated with lead poisoning, such as developmental delays and health complications.
Summary
Bill A07953 seeks to amend the insurance law and social services law in New York by ensuring that screenings for elevated lead levels in children are covered without the application of annual deductibles or coinsurance. This legislative change aims to facilitate access to lead screening for children and address public health concerns related to lead exposure, which can lead to serious health issues, particularly in young populations. By eliminating the financial barriers associated with these important screenings, the bill intends to promote early detection and intervention.
Contention
While the bill's intent to protect child health is broadly supported, there may be points of contention regarding its implementation and funding mechanisms. Critics may argue that such mandates could increase insurance premiums overall or strain state resources, as the costs of providing these screenings must be absorbed either by insurers or the state. Additionally, there may be discussions about the adequacy of public awareness campaigns needed to ensure that families seek these screenings, as simply having them available at no cost does not guarantee that all families will take advantage of them.
Requires that health insurance policies shall provide coverage for follow-up screening or diagnostic services for lung cancer; provides that no patient cost sharing shall be imposed for follow-up screening or diagnostic services for lung cancer.
Requires that health insurance policies shall provide coverage for follow-up screening or diagnostic services for lung cancer; provides that no patient cost sharing shall be imposed for follow-up screening or diagnostic services for lung cancer.
Requires the recommendation to a parent for blood lead level screenings of their child when a health care provider finds high lead levels in the blood of such child; directs the department of health to conduct an environmental investigation when a child is found to have high levels of lead in their blood.